New meetings & grants, with a focus on Vietnam, China, and the UK

Dear All: Below my signature, find details of 4 new meetings and (collectively) 4 active or upcoming grant opportunities. One of the grants has a 6 Sep deadline, so look quickly! At the very bottom of the email you will find an integrated summary of all upcoming meetings … there is a lot going on!

I hope to see you at next week’s ASM-ESCMID conference for the first episodes of the CARB-Xed + GARDP Bootcamp for Developers Series. Until then, all best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

 ————————————-
Meetings, two of which are preludes to grant competitions

  • 1 Oct 2017 and 2 Nov 2017 (London): BSAC: AMR Market Lounges. A pair of networking days focused on solutions to the AMR challenge.
  • 10 Oct 2017 (Hanoi): UK-Vietnam Newton Fund Pre-Call Workshop on Partnership for Infectious Disease Research 2017. This is a workshop in Hanoi in advance of a call for Newton Fund*-supported proposals from the collaboration between UK MRC and the -Vietnamese Ministry of Science and Technology (MOST).
  • 20 Nov 2017 (that week, in China): UK-China Newton Fund Workshop: Antimicrobial Resistance Centre Partnerships Initiative. This is a workshop in China in advance of a call for Newton Fund*-supported proposals from the collaboration between Research Councils UK (RCUK) and the National Natural Science Foundation of China (NSFC).
  • 20 Nov 2017 (London): Early Career Researcher Workshop on Diagnostics for Antimicrobial Resistance. This will be a one-day workshop for early career researchers which will include invited experts “to provide inspiration, encourage interdisciplinary networking, and explore the barriers and opportunities facing the development of rapid diagnostics for infectious disease.”

*The Newton Fund builds scientific and innovation partnerships with 16 partner countries to support their economic development and social welfare, and to develop their research and innovation capacity for long-term sustainable growth. It has a total UK Government investment of £735 million up until 2021, with matched resources from the partner countries. The Newton Fund is managed by the UK Department for Business, Energy and Industrial Strategy (BEIS), and delivered through 15 UK Delivery Partners, which include the Research Councils, the UK National Academies, the British Council, Innovate UK and the Met Office.

​ ————————————-
Other grant opportunities

​ ————————————-
Integrated summary of upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top